Immunovia Announces Positive Results From the IMMray PanCan-D Verification Study

Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, announced positive results from the verification study and will now commence the validation study, the last step towards the launch of IMMray PanCan-d. The verification study analysis shows results in line with the previous commercial test model study (CTMS), which paves the way for the final blinded validation study.

Recommended AI News: Daily AI Roundup: The 5 Coolest Things On Earth Today

“We are very pleased with the results of the verification study and are now commencing the preparation for the validation process, while finishing up some bioinformatics for all subgroups of samples,” said Mats Grahn, CEO. “These results will be made public as soon as the study is completed in all its details. We remain fully committed to the launch of IMMray™ PanCan-d and are now only one step away from the Q4 start sales of IMMray™ PanCan-d.”

Recommended AI News: ServiceNow Delivers New Native Workflows in Microsoft Teams to Power the Future of Work

The study was performed in order to verify the IMMray PanCan-d commercial biomarker signature using known samples and to further validate its accuracy in differentiating PDAC (pancreatic ductal adenocarcinoma) stages I through IV vs. controls that best mirror the clinical, commercial setting situation (i.e. patients with non-specific but concerning symptoms). All the samples were freshly collected through our Key Opinion Leaders (KOL) at pancreatic diseases reference sites in USA and Europe. The verification study precedes the final blinded validation study required for sales start.

Recommended AI News: ADT Invests in Percepta Labs, “Ethical AI” Security Technology Startup

Read More: Immunovia Announces Positive Results From the IMMray PanCan-D Verification Study

Notify of
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.